Q-omics provides the consensus-scored NACAP10 profile across patient tissues and cancer cell-line models. NACAP10 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, NACAP10 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, NACAP10 RNA expression shows 6,052 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, KIRC, and STAD as cancer lineages where NACAP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACAP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACAP10 survival associations across molecular data types. NACAP10 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACAP10 RNA expression–survival associations across cancer types. High NACAP10 expression shows unfavorable associations in LUSC and UCS, but favorable associations in ESCA, HNSC, THCA and LAML. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for NACAP10 RNA expression.
This table summarizes NACAP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NACAP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACAP10 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUSC and KICH. The KIRC box plot shows higher NACAP10 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .028).
This table shows molecular features associated with NACAP10 in patient tissues and cancer cell lines. In patient samples, NACAP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
